Premium
DiaPep277 ® Preserves Endogenous Insulin Production by Immunomodulation in Type 1 Diabetes
Author(s) -
ELIAS DANA,
AVRON ANN,
TAMIR MERANA,
RAZ ITAMAR
Publication year - 2006
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1375.052
Subject(s) - insulin , type 1 diabetes , beta cell , placebo , medicine , diabetes mellitus , endogeny , beta (programming language) , endocrinology , metabolic control analysis , pathology , islet , alternative medicine , computer science , programming language
DiaPep277 is an immunomodulatory peptide that arrests β cell destruction in mouse models of type 1 diabetes mellitus (T1DM). This article extends an original pilot observation to two studies of 61 patients (age > 16 years), diagnosed with T1DM within 6 months, and with measurable β cell function. Patients were treated with placebo ( n = 27) or 1.0 mg DiaPep277 ( n = 34). After 13 months, 1.0 mg Dia Pep277 treatment significantly ( P = 0.02) preserved β cell function as compared to the control with a trend for reduced HbA1c. This was achieved without an increase in insulin dose in the DiaPep277 group and with excellent safety. DiaPep277‐treated patients also had fewer Th1 DiaPep277‐specific T cells.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom